| abstract |
The present invention relates to a new compound of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: V 1 is C or N, V 2 is C(R 2 ) or N, whereby if V 1 is C then V 2 is N, if V 1 is C then V 2 is C(R 2 ), or if V 1 is N then V 2 is C(R 2 ); each n, k is independently 0, 1; each R 2 , R 11 is independently H, D, Hal, CN, NR′R″, C(O)NR′R″, C 1 -C 6 alkoxy; R 3 is H, D, hydroxy, C(O)C 1 -C 6 alkyl, C(O)C 2 -C 6 alkenyl, C(O)C 2 -C 6 alkynyl, C 1 -C 6 alkyl; R 4 is H, Hal, CN, CONR′R″, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy; L is CH 2 , NH, O or chemical bond; R 1 is selected from the group of the fragments, comprising: Fragment 1, Fragment 2, Fragment 3 each A 1 , A 2 , A 3 , A 4 is independently CH, N, CHal; each A 5 , A 6 , A 7 , A 8 , A 9 is independently C, CH or N; R 5 is H, CN, Hal, CONR′R″, C 1 -C 6 alkyl, non-substituted or substituted by one or more halogens; each R′ and R″ is independently selected from the group, comprising H, C 1 -C 6 alkyl, C 1 -C 6 cycloalkyl, aryl; R 6 is selected from the group: [formula II] each R 7 , R 8 , R 9 , R 10 is independently vinyl, methylacetylenyl; Hal is CI, Br, I, F, which have properties of inhibitor of Bruton's tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder. |